Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2020 Oct 22;10:17984. doi: 10.1038/s41598-020-75022-8

Temporal trends in clozapine use at time of discharge among people with schizophrenia at two public psychiatric hospitals in Taiwan, 2006–2017

Ching-Hua Lin 1,2, Hung-Yu Chan 3,4,✉, Chun-Chi Hsu 3, Feng-Chua Chen 1
PMCID: PMC7581717  PMID: 33093511

Abstract

Clozapine treatment remains the gold standard for treatment-resistant schizophrenia. This study aimed to describe temporal trends in clozapine use at discharge among patients with schizophrenia at two of the largest public psychiatric hospitals in Taiwan over a twelve-year period. Patients with schizophrenia discharged from the two study hospitals between 2006 and 2017 (n = 24,101) were included in the analysis. Antipsychotic augmentation was defined as concomitant use of a second antipsychotic as augmentation to clozapine treatment. Changes in the rate of clozapine use and antipsychotic augmentation at discharge over time were analyzed using the Cochran-Armitage trend test. Patients discharged on clozapine had significantly longer hospital stays than other patients. The rate of clozapine use at discharge increased from 13.8% to 20.0% over time (Z = 6.88, p < .0001). Concomitant use of anticholinergic medication was more common in patients receiving antipsychotic augmentation than clozapine antipsychotic monotherapy. Among patients discharged on clozapine, the rate of augmentation with a second antipsychotic increased from 19.1% to 36.2% over time (Z = 6.58, p < .0001). Among patients receiving antipsychotic augmentation, use of another second-generation antipsychotic as the augmentation agent grew from 32.6% to 65.5% over time (Z = 8.90, p < .0001). The increase in clozapine use was accompanied by an increase in concomitant use of a second antipsychotic as augmentation during the study period. Further studies are warranted to clarify the risk/benefit of this augmentation strategy. Clozapine may still be underutilized, and educational programs are needed to promote clinical use of clozapine.

Subject terms: Psychology, Diseases, Medical research

Introduction

With a worldwide prevalence of about 0.5–0.7%, schizophrenia is a common psychiatric disorder1,2, and antipsychotic medications are the cornerstone for the treatment of schizophrenia. However, treatment resistance to antipsychotic medications has been observed in approximately one-third of patients with schizophrenia3. Treatment-resistant schizophrenia (TRS) is commonly defined as lack of response to two or more antipsychotic trials of adequate dose (i.e., at least 600 mg chlorpromazine equivalent per day) and duration (i.e., at least 6 weeks)4. In comparison with other patients with schizophrenia, patients with TRS experience poorer quality of life, more comorbidities, and higher medical expenditures5.

Many agree clozapine is by far the most effective treatment for TRS6–8. Studies have shown it to be associated with significantly fewer extrapyramidal side effects which may account for the reduced treatment discontinuation rates9. Lower mortality rates, hospitalization rates and suicide risk are also seen6,10–12. Unfortunately, clozapine is often underused in patients with TRS despite its proven efficacy. Potential adverse effects, such as metabolic syndrome, bowel obstruction, agranulocytosis, pneumonia, and myocarditis may have limited its use13–15. With the aforementioned rate of treatment resistance in patients with schizophrenia, it is reasonable to expect that around 30% of the patients would be treated with clozapine, but this is far from reality. For example, 6.7% of patients with schizophrenia are treated with clozapine in Quebec16, 10.2% in Denmark17, 12.7% in India, 11% in Hong Kong18, and 23% in England and Wales19,20. Additionally, inadequate doses and treatment delays have also been reported6,21.

Nonetheless, not all patients with TRS will respond to clozapine antipsychotic monotherapy. It is estimated that approximately 40–70% of patients with TRS do not respond to clozapine antipsychotic monotherapy of adequate dose and duration22,23. In the absence of a clear consensus on what strategies to implement when facing clozapine failure, augmentation with a second antipsychotic is common in clinical practice22. The strategy of augmentation endeavors to enhance efficacy through exploiting different receptor-binding profiles among antipsychotics. Case in point, since clozapine has a lower affinity for dopamine D2 receptors and a faster dissociation rate from D2 receptors24, clozapine in combination with a second antipsychotic agent with a higher affinity for D2 receptors may enhance the efficacy25. Currently, in the event of clozapine antipsychotic monotherapy failure, rates of augmentation with a second antipsychotic agent fluctuate from 18 to 44%26,27.

The aim of this study was to illustrate the temporal trends in clozapine use and augmentation with a second antipsychotic to clozapine treatment at time of discharge among patients with schizophrenia discharged from two public psychiatric hospitals in Taiwan over a twelve-year period (2006–2017).

Methods

Ethics

The two public hospitals in southern and northern Taiwan respectively, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital (KSPH) and Taoyuan Psychiatric Center (TYPC), chosen for this study have the largest numbers of acute care psychiatric beds out of all the institutes in Taiwan. There are 7296 acute care psychiatric beds in Taiwan and the number of acute ward beds in the two study hospital is 786 (10.8%, 786/7296). It is our hope that the large sample size and its multi-regional (different areas of Taiwan) source would improve the representativeness of the study sample. The study was approved by the institutional review boards of both hospitals and was carried out in accordance with the Declaration of Helsinki (2013) as well as Taiwan’s national legislation (Human Subjects Research Act, Taiwan). Informed consents were waived by the ethics committees of the two study hospitals (Ethics Committee of Taoyuan Psychiatric Center and Institutional Review Board of Kaohsiung Municipal Kai-Syuan Psychiatric Hospital) as all data collected were part of routine clinical care and anonymized prior to analysis.

Subjects and design

Patients were considered eligible if they were discharged from an acute care ward to the community on antipsychotics between January 2006 and December 2017 with a DMS-IV-TR or DMS-5 diagnosis of schizophrenia or schizoaffective disorder28,29. Diagnoses were made by board-certified psychiatrists on the basis of clinical observations and interviews made during hospitalization, previous medical records and information provided by the patient’s primary caregiver. Patient data were retrospectively extracted from the medical records and the electronic health information system. Patients who did not have complete prescription data available or were in a clinical trial during the study period were excluded. The primary outcome measure was the antipsychotic medications the patient was on at discharge. As-needed (p.r.n.) medications were excluded from the analysis. As patients were usually discharged after a period of stabilization, these were the medications that the patient stabilized on. The antipsychotics used were grouped into first-generation (FGAs) and second-generation antipsychotics (SGAs). SGAs available at the two hospitals during the study period included risperidone, amisulpride, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, sulpiride30–32, ziprasidone and zotepine33.

Statistical analysis

Data were analyzed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA) and SAS 9.3 software (SAS institute Inc., Cary, North Carolina). Statistical significance was defined as a p-value < 0.05. The Pearson’s chi-squared test and the independent t test were used to compare demographic and clinical characteristics between groups.

The Cochran-Armitage trend test was used to evaluate whether statistically significant temporal trends existed for clozapine prescription rates between 2006 and 2017. For patients discharged on clozapine, we also performed the Cochran-Armitage trend test to evaluate whether statistically significant temporal trends existed for rates of augmentation with a second antipsychotic (FGA or SGA) among patients treated with clozapine.

In order to validate the primary analysis examining trends in clozapine use and clozapine antipsychotic augmentation at discharge, three sensitivity analyses were conducted34. In the first analysis, for patients with multiple hospitalizations during the study period only the last hospitalization was included. This is due to the fact that clozapine is often viewed as a “drug of last resort” in clinical practice35. For the second and third analysis, only the patients discharged from a single study hospital, KSPH and TYPC respectively, were included.

Ethical standards

The study was approved by the institutional review boards (IRB) of both Kaohsiung Municipal Kai-Syuan Psychiatric Hospital and Taoyuan Psychiatric Center and was carried out in accordance with the Declaration of Helsinki (2013) as well as Taiwan’s national legislation (Human Subjects Research Act). IRB Number: B20170929.

Informed consent

Informed consents were not acquired as all data collected were part of routine clinical care and anonymized prior to analysis.

Results

Descriptive statistics

A total of 24, 840 patients with schizophrenia or schizoaffective disorder were discharged from the two study hospitals during the study period, and 24,101 were included in the analysis. Table 1 lists the demographic and clinical characteristics of these patients. Among the 24,101 patients included in the analysis, 4248 (17.6%) were discharged on clozapine. Eleven thousand, three hundred and sixty-one (47.1%) were male, and 12,740 (52.9%) were female. The mean age was 41.4 ± 12.2 years.

Table 1.

Demographic and clinical characteristics of the study population.

All patients (n = 24,101) KSPHa patients (n = 13,476) TYPCb patients (n = 10,625) Pc
n % n % n %
Sex  < 0.001 
 Male 11,361 47.1 5811 43.1 5550 52.2
 Female 12,740 52.9 7665 56.9 5075 47.8
Discharged on clozapine  < 0.001 
 Yes 4248 17.6 2249 16.7 1999 18.8
 No 19,853 82.4 11,227 83.3 8626 81.2
Mean SD Mean SD Mean SD Pd
Age (years) 41.4 12.2 43.2 11.8 39.2 12.2  < 0.001
Length of hospital stay (days) 179.3 446.2 173.5 386.5 186.6 512.0 0.024
Clozapine daily dose (mg) 268.4 138.2 234.1 120.8 307.0 146.2  < 0.001
Open in a new tab

Bold, statistically significant.

aKSPH = Kai-Syuan Psychiatric Hospital.

bTYPC = Taoyuan Psychiatric Center.

cPearson’s χ2 test.

dIndependent t test.

There were significant differences between patients discharged from the two study hospitals on several variables (Table 1). Patients discharged from KSPH were older and more likely to be female. In addition, they had a shorter length of hospital stay and were less likely to be on clozapine at discharge. Among patients receiving clozapine treatment, the daily dose was significantly lower in those discharged from KSPH.

Patients discharged on clozapine versus others

Comparisons between patients discharged on clozapine and others in demographic and clinical characteristics are shown in Table 2. There was no statistically significant difference between the two groups with respect to sex or age. Compared with other patients, patients discharged on clozapine had significantly longer hospital stays. Table 3 lists the percentage of patients discharged on clozapine each year between 2006 and 2017. The results of the Cochrane-Armitage trend test showed a significant increasing trend in clozapine use at discharge (Z = 6.88, p < 0.0001). Supplemental Fig. 1 illustrates temporal trends in clozapine use at discharge among KSPH, TYPC, and all patients.

Table 2.

Comparisons between patients discharged on clozapine and others.

Patients discharged on clozapine (n = 4248) Others (n = 19853) pa
n % n %
Sex 0.230
 Male 1967 46.3 9394 47.3
 Female 2281 53.7 10459 52.7
Mean SD Mean SD pb
Age (years) 41.6 11.0 41.4 12.4 0.302
Length of hospital stay (days) 350.5 672.6 142.7 370.5 < 0.001
Open in a new tab

Bold, statistically significant

aPearson’s χ2 test

bIndependent t test.

Table 3.

Percentage of patients discharged on clozapine, 2006–2017.

Year 2006 2007 2008 2009 2010 2011
No. of patients discharged on clozapine (%) 241 (13.8%) 287 (15.1%) 321 (15.2%) 342 (16.8%) 363 (17.4%) 345 (17.1%)
No. of patients discharged 1752 1898 2113 2035 2088 2021
Year 2012 2013 2014 2015 2016 2017
No. of patients discharged on clozapine (%) 410 (19.4%) 395 (19.6%) 420 (20.2%) 346 (17.3%) 386 (19.1%) 392 (20.0%)
No. of patients discharged 2117 2015 2077 2004 2024 1957
Open in a new tab

Clozapine antipsychotic monotherapy versus augmentation with a second antipsychotic

Among the 4,248 patients discharged on clozapine, 1,374 (32.3%) were also prescribed a second antipsychotic as augmentation to clozapine treatment. Antipsychotics used for augmentation are listed in Supplementary Table S1 online. In contrast, 2,874 (67.7%) patients received clozapine antipsychotic monotherapy. Table 4 lists the differences in demographic and clinical characteristics between the two groups. The female gender was overrepresented in patients receiving augmentation therapy. Patients receiving augmentation therapy were also more likely to be on an anticholinergic agent and received lower doses of clozapine. However, the observed differences in clozapine dose between the two groups were quite small. No statistically significant differences existed between the two groups in terms of age or length of hospital stay. The Cochrane-Armitage trend test results revealed that there was a significant increase in using a second antipsychotic as augmentation among patients discharged on clozapine during the study period (Z = 6.58, p < 0.0001).

Table 4.

Comparisons between patients receiving augmentation therapy and antipsychotic monotherapy among patients discharged on clozapine.

Augmentation therapy n = 1374) Antipsychotic monotherapy (n = 2874) pa
n % n %
Sex  < 0.001
 Male 560 40.8 1407 49.0
 Female 814 59.2 1467 51.0
Use of anticholinergics  < 0.001
 Yes 665 48.4 658 22.9
 No 709 51.6 2216 77.1
Mean SD Mean SD pb
Age (years) 41.3 10.9 41.8 11.1 0.230
Length of hospital stay (days) 330.7 636.2 360.0 689.3 0.184
Clozapine daily dose (mg) 261.3 155.5 271.8 129.0 0.021
Open in a new tab

Bold, statistically significant.

aPearson’s χy2 test.

bIndependent t test.

Clozapine + another SGA versus clozapine + an FGA

Among the 1,374 patients receiving a second antipsychotic as augmentation to clozapine treatment, another SGA was used in 668 (48.6%), while an FGA was used in 706 (51.4%). Patients who received augmentation with another SGA were older and less likely to be on anticholinergics (Supplementary Tables S1& S1 online). There was also a significant increase in using another SGA as the augmentation agent, going from 32.6% to 65.5% over the study period (Z = 8.90, p < 0.0001) among patients receiving augmentation therapy. The rates of antipsychotic augmentation among patients discharged on clozapine and the rates of using another SGA as the augmentation agent are shown in Table 5.

Table 5.

Rate of augmentation with a second antipsychotic among patients discharged on clozapine and rate of SGAa augmentation among all augmentation patients, 2006–2017.

Year 2006 2007 2008 2009 2010 2011
No. of patients discharged on clozapine + a second antipsychotic (%) 46 (19.1) 70 (24.4) 90 (28.0) 104 (30.4) 123 (33.9) 121 (35.1)
No. of patients discharged on clozapine + a second SGAa (%) 15 (32.6%) 26 (37.1%) 24 (26.7%) 32 (30.8%) 44 (35.8%) 54 (44.6%)
No. of patients discharged on clozapine 241 287 321 342 363 345
Year 2012 2013 2014 2015 2016 2017
No. of patients discharged on clozapine + a second antipsychotic (%) 107 (26.1) 126 (31.9) 146 (34.8) 148 (42.8) 151 (39.1) 142 (36.2)
No. of patients discharged on clozapine + a second SGAb (%) 54 (50.5%) 66 (52.4%) 76 (52.1%) 86 (58.1%) 98 (64.9%) 93 (65.5%)
No. of patients discharged on clozapine 410 395 420 346 386 392
Open in a new tab

aFGA = Firs-generation antipsychotic.

bSGA = Second-generation antipsychotic.

Sensitivity analyses

The results of the sensitivity analyses were consistent with the primary analysis. When only the last hospitalization of each subject was included in the analysis, the results still showed significant increasing trends in clozapine use at discharge (Z = 4.60, p < 0.0001) (Supplementary Table S3 online) and use of a second antipsychotic as augmentation to clozapine therapy (Z = 4.36, p < 0.0001) (Supplementary Table S4 online). In addition, when only patients from a single study hospital, KSPH and TYPC respectively, were included in the analysis, both hospitals saw significant increases in clozapine use (Z = 5.14, p < 0.0001 for KSPH; Z = 4.75, p < 0.0001 for TYPC) (Supplementary Tables S5 & S7 online) and use of a second antipsychotic as augmentation (Z = 4.63, p < 0.0001 for KSPH; Z = 4.79, p < 0.0001 for TYPC) (Supplementary Tables S6 & S8 online).

Discussion

The main finding of this study was that the percentage of patients discharged on clozapine increased from 13.8% to 20.0% between 2006 and 2017. This is consistent with the results of the study by Bachmann et al.36. They concluded a rise in clozapine prescription was seen in most countries from 2005 to 2014. This boost perhaps reflects the gained experience and success with this drug among clinicians in treating patients with TRS. Keeping in mind that treatment resistance is seen in up to a third of schizophrenia patients3, it stands to reason that around 30% of schizophrenia patients should be prescribed clozapine. In addition, clozapine is the only antipsychotic proven effective for recurrent suicidal behavior in schizophrenia patients37. Therefore, with an average prescription rate of only 17.6%, clozapine may have been underutilized at the two study hospitals.

The many possible adverse effects of clozapine have often led it to be seen as a last resort. Clinicians generally go through multiple failed trials of other antipsychotics prior to initiation of clozapine35. This could be an explanation for why patients discharged on clozapine had longer hospital stays in this study (Table 2).

In the current study, length of hospital stay (179.3 ± 446.2 days) (Table 1) was extended for all patients with schizophrenia. This may be a direct result of the reality that community-based mental health services are still somewhat under-developed in Asia, and long-term institutionalization of psychiatric patients is more common than in western countries38. For example, the average length of stay for psychiatric hospitalization in Japan was 274 days in 201839.

According to the World Health Organization, the defined daily dose for clozapine is 300 mg/d40,41, which is higher than the average clozapine dose (268.4 ± 138.2 mg) observed in this study (Table 1). One possible explanation for this phenomenon is that metabolism of clozapine may be slower in Asians42,43. Whether such dosages are adequate in Asian patients could be confirmed by future studies focused on plasma clozapine levels4. Furthermore, the prevalence of cigarette smoking and nicotine replacement therapy among psychiatric inpatients in Taiwan is unlike other countries44. The results of a meta-analysis of studies across 20 nations showed the prevalence of current smoking in patients with schizophrenia was 62%45. However, in Taiwan the prevalence of current smoking in patients with schizophrenia was only 38.1%46 which was considerably lower. Previous studies showed that clozapine plasma concentration levels are 35–48% lower in cigarette smokers compared to non-smokers47. These observations could be the reason behind the lower average dose of clozapine seen in this study.

We also found the proportion of clozapine-treated patients receiving augmentation with a second antipsychotic had steadily increased throughout the study period, going from 19.1% to 36.2% (Table 5). The percentage of patients receiving antipsychotic augmentation in this study, i.e., 32.3%, was in the same ballpark as a UK study that declared 30%48. By the end of the study period, the percentage of patients using a second SGA as the augmentation agent among all augmentation patients had also increased significantly (32.2–65.5% ) (Table 5). This finding may be interpreted in several different ways.

It may reflect the fact that many patients treated with clozapine are clinically complex which necessitates treatment with high doses and polypharmacy, sometimes at the expense of increased side-effect burden49. Furthermore, chronicity, treatment resistance and comorbid conditions are often more common among patients in public institutions50. In real-world clinical practice, especially in a setting such as public psychiatric hospitals, from time to time clinicians will encounter schizophrenia patients with prominent impulsivity and aggression that simply do not respond to clozapine. Under these circumstances, augmentation with a second antipsychotic may be the only viable option even though there is currently no consensus regarding such a strategy22.

As clozapine in some patients may take longer than the usual 4–8 weeks to achieve clinical response49,51, clinicians may resort to augmentation with a second antipsychotic to speed up symptom reduction in order to satisfy patient expectations and healthcare policies.

It must be said that the decision to use an augmentation agent is not always due to incomplete response to clozapine. In this study, the average clozapine dose used in patients receiving augmentation therapy (261.8 mg/d) (Table 4) was considerably lower than the recommended threshold for establishing non-response to clozapine treatment. When plasma clozapine levels are unavailable, Howes and colleagues4 recommend that a minimum dosage of 500 mg/d should be tried for at least 3 months prior to establishing treatment resistance to clozapine. Clinicians are often hesitant to use higher doses of clozapine because of dose-related adverse effects, such as seizure, sedation, tachycardia, orthostatic hypotension, nocturnal enuresis and sialorrhea52,53. Augmentation strategy may be adopted with the expectation to reduce symptom severity without increasing the clozapine dose, thus avoiding dose-related adverse effects of clozapine49. However, compared with patients receiving clozapine antipsychotic monotherapy, concomitant use of anticholinergics was more common in those receiving antipsychotic augmentation (Table 4). Anticholinergic agents are generally used to treat extrapyramidal side effects (EPSE). It is possible that the augmentation strategy causes more EPSE than clozapine antipsychotic monotherapy. In addition, clozapine itself also has significant anticholinergic properties. This finding is clinically relevant because antipsychotic augmentation may lead to more anticholinergic side effects, such as dry mouth, constipation, urinary retention, and cognitive impairment. Finally, different individuals may exhibit highly diverse responses to augmentation with a second antipsychotic. Some clozapine partial responders may indeed benefit from such augmentation strategy54.

In this study, use of a second SGA as the augmentation agent to clozapine treatment steadily became more common among patients receiving antipsychotic augmentation (Table 5). Use of anticholinergics was less common in patients receiving SGA augmentation than those receiving FGA augmentation (Table S2). Additionally, the rate of SGA augmentation increased gradually during the study period (Table 5). One possibility is that SGAs may cause fewer EPSE than FGAs, thus are more appealing to patients and clinicians as an augmentation agent to clozapine55.

To the best of our knowledge, this is the first study to investigate temporal trends in both clozapine use among patients with schizophrenia and the rates of antipsychotic augmentation among patients on clozapine. The results could help paint a clearer picture regarding clinical use of clozapine. Another strength of our study was that given the large sample size (n = 24,101) there was enough statistical power to help reduce type II error. Additionally, use of an inpatient-only sample ensured medication adherence as it was reliably monitored by the nursing staff.

However, some limitations should be considered while interpreting the results of this study. First, this was a study of retrospective design, and the sample was not randomized. Second, we did not control for the effects of concomitant use of other psychotropics that may be relevant to the analysis, including antidepressants, mood stabilizers and glutamatergic agents56. Third, this was a hospital-based study, and only inpatients were included. As inpatients are prone to be more severely/chronically ill and/or treatment-resistant, the findings of this study may not be generalizable to outpatients. Fourth, as both of the study sites were large public psychiatric hospitals, generalizability of the findings to general hospitals may be limited. Fifth, it is possible patients were in the process of cross tapering from a previous antipsychotic to clozapine at discharge, and the study design did not take this into account. However, the number of these patients would be minimal as it is common practice at both study hospitals to discharge patients only after reaching the maintenance phase of treatment57. The extended length of hospital stay for patients discharged on clozapine (350.5 ± 672.6 days) (Table 1) also lends support to this line of thinking. Sixth, in the analysis patients were counted multiple times if they had multiple hospitalizations during the study period. In addition, there were significant differences in some clinical characteristics between patients at the two study hospitals (Table 1). These were all potential confounders for the study. However, the three sensitivity analyses consistently demonstrate that both clozapine use and clozapine antipsychotic augmentation increased significantly during the study period, same as the primary analysis. Therefore, results of the primary analysis remained robust despite these potential confounders. Lastly, data on some important clinical characteristics were not collected in this study, e.g., treatment duration, symptom severity, functional impairment, risk of suicide or violence, adverse events and comorbidity.

Conclusion

In conclusion, we found that clozapine was still underused, and when used it was often at an inadequate dosage. Additionally, patients discharged on clozapine had longer hospital stays than other patients. Educational programs for professionals, patients and family members are vital to promote proper use of clozapine58. More studies are needed to address the implementation of effective strategies to facilitate clinical use of clozapine. The surge in clozapine use went hand in hand with an increase in the percentage of patients receiving augmentation with a second antipsychotic. Antipsychotic augmentation has grown in popularity, especially strategies that involve a second SGA. However, concomitant use of anticholinergics was more common in patients receiving antipsychotic augmentation than those receiving antipsychotic monotherapy. Further research is warranted to examine the relationship between risks and benefits and also the cost-effectiveness of this augmentation strategy.

Supplementary information

Supplementary Information 1. (15KB, docx)
Supplementary Information 2. (142.3KB, tif)
Supplementary Information 3. (49.4KB, docx)

Acknowledgements

None.

Author contributions

C-H.L, F-C.C and H-Y.C designed the study and wrote the protocol of the manuscript. C-H.L and F-C.C collected all of the data. C-H.L and H-Y.C undertook the statistical analysis. C-H.L, C-C.H and H-Y.C managed the literature searches and analyses. C-H.L wrote the first draft of the manuscript. C-C.H and H-Y.C revised the first draft of the manuscript and finalized. All authors contributed to and have approved the final manuscript.

Funding

This work was supported by a grant from Taiwan Ministry of Health and Welfare (MOHW-107-47). The Ministry of Health and Welfare played no role in study design; collection, analysis and interpretation of data; writing of the report; and the decision to submit the paper for publication.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

is available for this paper at 10.1038/s41598-020-75022-8.

References

  • 1.McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 2008;30:67–76. doi: 10.1093/epirev/mxn001. [DOI] [PubMed] [Google Scholar]
  • 2.Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990 horizontal line 2013: a systematic literature review. BMC Psychiatry. 2015;15:193. doi: 10.1186/s12888-015-0578-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Elkis H, Buckley PF. Treatment-resistant schizophrenia. Psychiatr. Clin. N. Am. 2016;39:239–265. doi: 10.1016/j.psc.2016.01.006. [DOI] [PubMed] [Google Scholar]
  • 4.Howes OD, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–229. doi: 10.1176/appi.ajp.2016.16050503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int. Clin. Psychopharmacol. 2014;29:63–76. doi: 10.1097/YIC.0b013e32836508e6. [DOI] [PubMed] [Google Scholar]
  • 6.Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br. J. Psychiatry. 2011;198:247–249. doi: 10.1192/bjp.bp.110.088690. [DOI] [PubMed] [Google Scholar]
  • 7.Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796. doi: 10.1001/archpsyc.1988.01800330013001. [DOI] [PubMed] [Google Scholar]
  • 8.Siskind D, McCartney L, Goldschlager R, Kisely SC, V, first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry. 2016;209:385–392. doi: 10.1192/bjp.bp.115.177261. [DOI] [PubMed] [Google Scholar]
  • 9.Chan HY, Pan YJ, Chen JJ, Chen CH. Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic comparative study. J. Clin. Psychopharmacol. 2017;37:13–20. doi: 10.1097/JCP.0000000000000623. [DOI] [PubMed] [Google Scholar]
  • 10.Vermeulen JM, et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 11.–12.5 years. Schizophr Bull. 2019;45:315–329. doi: 10.1093/schbul/sby052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Tiihonen J, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) Lancet. 2009;374:620–627. doi: 10.1016/S0140-6736(09)60742-X. [DOI] [PubMed] [Google Scholar]
  • 12.Land R, et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr. Scand. 2017;135:296–309. doi: 10.1111/acps.12700. [DOI] [PubMed] [Google Scholar]
  • 13.Remington G, et al. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert. Opin. Drug Saf. 2016;15:1193–1203. doi: 10.1080/14740338.2016.1191468. [DOI] [PubMed] [Google Scholar]
  • 14.Farooq S, Choudry A, Cohen D, Naeem F, Ayub M. Barriers to using clozapine in treatment-resistant schizophrenia: systematic review. Br. J. Psychol. Bull. 2019;43:8–16. doi: 10.1192/bjb.2018.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chan HY, Lai CL, Lin YC, Hsu CC. Is antipsychotic treatment associated with risk of pneumonia in people with serious mental illness? The roles of severity of psychiatric symptoms and global functioning. J. Clin. Psychopharmacol. 2019;39:434–440. doi: 10.1097/JCP.0000000000001090. [DOI] [PubMed] [Google Scholar]
  • 16.Latimer E, et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec. Clin. Schizophr. Relat. Psychoses. 2013;7:33–41. doi: 10.3371/CSRP.LAWY.012513. [DOI] [PubMed] [Google Scholar]
  • 17.Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur. Neuropsychopharmacol. 2012;22:818–824. doi: 10.1016/j.euroneuro.2012.03.003. [DOI] [PubMed] [Google Scholar]
  • 18.Xiang YT, et al. Clozapine use in schizophrenia: findings of the Research on Asia Psychotropic Prescription (REAP) studies from 2001 to 2009. Aust. N. Z. J. Psychiatry. 2011;45:968–975. doi: 10.3109/00048674.2011.607426. [DOI] [PubMed] [Google Scholar]
  • 19.Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin. Schizophr. Relat. Psychoses. 2010;4:49–55. doi: 10.3371/CSRP.4.1.4. [DOI] [PubMed] [Google Scholar]
  • 20.Patel MX, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur. Neuropsychopharmacol. 2014;24:499–509. doi: 10.1016/j.euroneuro.2014.01.014. [DOI] [PubMed] [Google Scholar]
  • 21.Howes OD, et al. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br. J. Psychiatry. 2012;201:481–485. doi: 10.1192/bjp.bp.111.105833. [DOI] [PubMed] [Google Scholar]
  • 22.Barber S, Olotu U, Corsi M, Cipriani A. Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. Cochrane Database Syst. Rev. 2017;3:CD006324. doi: 10.1002/14651858.CD006324.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can. J. Psychiatry. 2017;62:772–777. doi: 10.1177/0706743717718167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry. 2001;158:360–369. doi: 10.1176/appi.ajp.158.3.360. [DOI] [PubMed] [Google Scholar]
  • 25.Muscatello MR, et al. Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opin. Pharmacother. 2014;15:2329–2345. doi: 10.1517/14656566.2014.956082. [DOI] [PubMed] [Google Scholar]
  • 26.Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J. Clin. Psychiatry. 2004;65:1597–1600. doi: 10.4088/jcp.v65n1203. [DOI] [PubMed] [Google Scholar]
  • 27.Buckley P, et al. When symptoms persist: clozapine augmentation strategies. Schizophr. Bull. 2001;27:615–628. doi: 10.1093/oxfordjournals.schbul.a006901. [DOI] [PubMed] [Google Scholar]
  • 28.APA. Diagnostic and statistical manual of mental disorders : DSM-IV-TR. 4th ed., text revision. edn, (American Psychiatric Association, 2000).
  • 29.APA. Diagnostic and statistical manual of mental disorders : DSM-5. (American Psychiatric Pub, 2013).
  • 30.Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr. Scand. 2010;122:356–366. doi: 10.1111/j.1600-0447.2010.01576.x. [DOI] [PubMed] [Google Scholar]
  • 31.Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf. 1996;14:288–298. doi: 10.2165/00002018-199614050-00003. [DOI] [PubMed] [Google Scholar]
  • 32.Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst. Rev. 2009 doi: 10.1002/14651858.CD007811. [DOI] [PubMed] [Google Scholar]
  • 33.Stahl, S. M. Stahl’s Essential Psychopharmacology: Prescriber’s Guide. Fifth edition. edn, (2014).
  • 34.Thabane L, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med. Res. Methodol. 2013;13:92. doi: 10.1186/1471-2288-13-92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Harrison J, Janlov M, Wheeler AJ. Patterns of clozapine prescribing in a mental health service in New Zealand. Pharm. World Sci. 2010;32:503–511. doi: 10.1007/s11096-010-9398-5. [DOI] [PubMed] [Google Scholar]
  • 36.Bachmann CJ, et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr. Scand. 2017;136:37–51. doi: 10.1111/acps.12742. [DOI] [PubMed] [Google Scholar]
  • 37.Tang Y, et al. Prescribing of clozapine and antipsychotic polypharmacy for schizophrenia in a large medicaid program. Psychiatr. Serv. 2017;68:579–586. doi: 10.1176/appi.ps.201600041. [DOI] [PubMed] [Google Scholar]
  • 38.Xiang YT, Ungvari GS, Correll CU, Chiu HF, Shinfuku N. Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiol. Psychiatr. Sci. 2016;25:9–17. doi: 10.1017/S2045796015000694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Shinfuku N. A History of Mental Health Care in Japan: International Perspectives. Taiwanese J Psychiatry. 2019;33:179. doi: 10.4103/TPSY.TPSY_43_19. [DOI] [Google Scholar]
  • 40.WHO. ATC/DDD Index N05A Antipsychotics. Available online at: https://www.whocc.no/ (2017).
  • 41.Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr. Bull. 2016;42:S90–S94. doi: 10.1093/schbul/sbv167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Subramaniam M, et al. Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum. Psychopharmacol. 2007;22:217–222. doi: 10.1002/hup.842. [DOI] [PubMed] [Google Scholar]
  • 43.Faden J. Treatment-resistant schizophrenia: a brief overview of treatment options. J Clin Psychiatry. 2019 doi: 10.4088/JCP.18ac12394. [DOI] [PubMed] [Google Scholar]
  • 44.Chan H, Chen JJ, Pan YJ, Hsu CC. Nicotine replacement therapy and healthy lifestyle psychoeducation for smoking reduction in acute psychiatric inpatients: a cluster-randomized parallel study. J. Clin. Psychopharmacol. 2020;40:149–156. doi: 10.1097/jcp.0000000000001170. [DOI] [PubMed] [Google Scholar]
  • 45.de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–157. doi: 10.1016/j.schres.2005.02.010. [DOI] [PubMed] [Google Scholar]
  • 46.Wu EL, et al. Smoking behaviors among psychiatric inpatients in Taiwan. Taiwan J. Psychiatry. 2013;27:238–244. [Google Scholar]
  • 47.Mayerova M, et al. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatr. Dis. Treat. 2018;14:1535–1543. doi: 10.2147/NDT.S163839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wilson S, et al. Clozapine antipsychotic polypharmacy: audit of use and patient monitoring. Psychiatrist. 2013;37:322–325. doi: 10.1192/pb.bp.112.040352. [DOI] [Google Scholar]
  • 49.Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr. Scand. 2011;123:411–422. doi: 10.1111/j.1600-0447.2011.01710.x. [DOI] [PubMed] [Google Scholar]
  • 50.Patrick V, Schleifer SJ, Nurenberg JR, Gill KJ. Best practices: an initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr. Serv. 2006;57:21–23. doi: 10.1176/appi.ps.57.1.21. [DOI] [PubMed] [Google Scholar]
  • 51.Fabrazzo M, et al. Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002;27:1050–1055. doi: 10.1016/S0893-133X(02)00319-6. [DOI] [PubMed] [Google Scholar]
  • 52.Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: When is it warranted and how can it be avoided? J. Clin. Psychiatry. 2013;74:603–613. doi: 10.4088/JCP.12r08064. [DOI] [PubMed] [Google Scholar]
  • 53.Citrome L, McEvoy JP, Saklad SR. A guide to the management of clozapine-related tolerability and safety concerns. Clin. Schizophr. Relat. Psychoses. 2016;10:163–177. doi: 10.3371/CSRP.SACI.070816. [DOI] [PubMed] [Google Scholar]
  • 54.Srisurapanont M, Suttajit S, Maneeton N, Maneeton B. Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials. J. Psychiatr. Res. 2015;62:38–47. doi: 10.1016/j.jpsychires.2015.01.004. [DOI] [PubMed] [Google Scholar]
  • 55.Miyamoto, S., Duncan, G. E., Goff, D. C. & Lieberman, J. A. Therapeutics of schizophrenia. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins, 775–807 (2002).
  • 56.Lerner, V. & Miodownik, C. in Polypharmacy in Psychiatry Practice, Volume II 109–143 (Springer, 2013).
  • 57.Lehman AF, et al. Practice guideline for the treatment of partients with schizophrenia. Am. J. Psychiatry. 2004;161:i–iv. [PubMed] [Google Scholar]
  • 58.Freudenreich O, Henderson DC, Sanders KM, Goff DC. Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Acad. Psychiatry. 2013;37:27–30. doi: 10.1176/appi.ap.11090159. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information 1. (15KB, docx)
Supplementary Information 2. (142.3KB, tif)
Supplementary Information 3. (49.4KB, docx)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES